With the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.
Mariel Metcalfe
Advertisement
Mariel Metcalfe is Head of Living With at Research Partnership.
Articles by Mariel Metcalfe
Advertisement
Latest Updated Articles
NASH: Pointers for Pharma from the Patient PerspectivePublished: October 3rd 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
Is FDA Streamlining Regulations in the Biosimilar Space?
4
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
5
